Lyra Therapeutics Inc (LYRA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2021 | 09-2021 | 06-2021 | 03-2021 | 12-2020 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -43,513 | -29,896 | -18,841 | -7,802 | -22,127 |
| Depreciation Amortization | 1,001 | 723 | 373 | 70 | 95 |
| Accounts payable and accrued liabilities | 2,350 | 1,167 | 743 | 452 | 345 |
| Other Working Capital | 13,922 | 12,662 | 13,004 | -457 | -879 |
| Other Operating Activity | 420 | 821 | 512 | 147 | 1,423 |
| Operating Cash Flow | $-25,820 | $-14,523 | $-4,209 | $-7,590 | $-21,143 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -3,385 | -2,302 | -1,785 | -1,160 | -1,775 |
| Investing Cash Flow | $-3,385 | $-2,302 | $-1,785 | $-1,160 | $-1,775 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 604 | 604 | 593 | 262 | 59,900 |
| Other Financing Activity | -245 | -241 | -146 | 0 | 27,803 |
| Financing Cash Flow | $359 | $363 | $447 | $262 | $87,703 |
| Beginning Cash Position | 74,922 | 74,922 | 74,922 | 74,922 | 10,137 |
| End Cash Position | 46,076 | 58,460 | 69,375 | 66,434 | 74,922 |
| Net Cash Flow | $-28,846 | $-16,462 | $-5,547 | $-8,488 | $64,785 |
| Free Cash Flow | |||||
| Operating Cash Flow | -25,820 | -14,523 | -4,209 | -7,590 | -21,143 |
| Capital Expenditure | -3,385 | -2,302 | -1,785 | -1,160 | -1,775 |
| Free Cash Flow | -29,205 | -16,825 | -5,994 | -8,750 | -22,918 |